Bellicum Pharmaceuticals, which is developing adjunct cancer immunotherapies based on a conditionally responsive platform, announced terms for its IPO on Tuesday. The Houston, TX-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Bellicum Pharmaceuticals would command a fully diluted market value of $424 million.
Bellicum Pharmaceuticals, which was founded in 2004 and booked $3 million in sales for the 12 months ended September 30, 2014, plans to list on the NASDAQ under the symbol BLCM. Jefferies, Citi and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of December 15, 2014.
